Accounting for patient- (e.g., age, sex, comorbidities) and tumour-specific (e.g., Human epidermal growth factor receptor-2 [HER-2]-positivity) factors would also be essential to counter effect modification in mortality, surgical activity- or procedure backlog outcomes. The gene discussed is ERBB2; the disease is neoplasm.